Improvement of doxorubicin radioiodination and in-vivo cancer suppression via loading in nanosilver system

Appl Radiat Isot. 2022 Sep:187:110288. doi: 10.1016/j.apradiso.2022.110288. Epub 2022 May 16.

Abstract

This study aimed at improving the radioiodination of doxorubicin (DOX) and its localization in cancer cell for theranostic purposes. To achieve this goal, a composite of DOX with polyvinyl pyrrolidone (PVP) and silver nanoparticles (AgNPs) was prepared. Both DOX and (DOX/PVP/AgNPs) were radiolabelled with iodine-125 [125I] and optimized using iodogen as a preferable oxidizing agent. The maximum obtained radiochemical yields for both systems were 79.9% and 96.6%, respectively. Interestingly, the biodistribution study revealed that [125I]DOX/PVP/AgNPs had an effective localization on tumors. Moreover, Target/control target (T/CT) ratio of [125I] DOX/PVP/AgNPs showed the highest value of 9.1 at 1 h post injection, suggesting that [125I]DOX/PVP/AgNPs has a great potential as a proposed tumor targeting agent.

Keywords: Biodistribution; Doxorubicin; Radioiodination; Silver nanoparticle composite; Tumor localization.

MeSH terms

  • Doxorubicin
  • Humans
  • Iodine Radioisotopes
  • Metal Nanoparticles*
  • Nanoparticles*
  • Neoplasms*
  • Povidone
  • Silver
  • Tissue Distribution

Substances

  • Iodine Radioisotopes
  • Silver
  • Doxorubicin
  • Povidone